Therefore, under inflammatory conditions, SPARC mainly aggravates intestinal mucosal barrier damage by promoting the degradation of TJ proteins, thus confirming that SPARC can disrupt the intestinal barrier to promote CD progression. This evidence concerns the gene SPARC and Cowden disease.